Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1593 - Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM): a post hoc analysis of the WJOG4407G phase III study

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Immunotherapy

Tumour Site

Colon and Rectal Cancer

Presenters

Ayumu Hosokawa

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

A. Hosokawa1, K. Yamazaki2, C. Matsuda3, S. Ueda4, H. Fujii5, E. Baba6, S. Okamura7, M. Tsuda8, T. Tamura9, K. Shinozaki10, T. Tsushima2, T. Tsuda11, T. Shirakawa12, H. Yamashita13, S. Morita14, K. Muro15

Author affiliations

  • 1 Department Of Medical Oncology, University of Miyazaki, 889-1692 - Miyazaki/JP
  • 2 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 3 Department Of Surgery, Osaka General Medical Center, 558-8558 - Osaka/JP
  • 4 Department Of Medical Oncology, Kindai University Nara Hospital, Nara/JP
  • 5 Clinical Oncology, Jichi Medical University, 329-0498 - Shimotsuke/JP
  • 6 Comprehensive Clinical Oncology, Kyushu University Hospital, Fukuoka/JP
  • 7 Department Of Surgery, Suita Municipal Hospital, Suita/JP
  • 8 Department Of Gastroenterological Oncology, Hyogo Cancer Center, 673-8558 - Hyogo/JP
  • 9 Department Of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama/JP
  • 10 Division Of Clinical Oncology, Hiroshima Prefectural Hospital, 734-8530 - Hiroshima/JP
  • 11 Department Of Clinical Oncology, St Marianna University School of Medicine, Kawasaki/JP
  • 12 Department Of Chemotherapy, Miyazaki Prefectural Miyazaki Hospital, Miyazaki/JP
  • 13 Department Of Gastroenterology And Hepatology, National Hospital Organization Okayama Medical Center, Okayama/JP
  • 14 Department Of Biomedical Statistics And Bioinformatics, Kyoto University Graduate School of Medicine, 606-8507 - Kyoto/JP
  • 15 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
More

Resources

Abstract 1593

Background

The phase III WJOG4407G study showed non-inferiority of FOLFIRI plus bevacizumab to mFOLFOX6 plus bevacizumab in progression-free survival, as the first-line chemotherapy for patients with metastatic colorectal cancer. The aim of this study was to evaluate the predictive and prognostic value of morphologic response to first-line chemotherapy containing bevacizumab in patients with CLM.

Methods

This study is a post hoc analysis of patients from the WJOG4407G study. Morphologic response was assessed with the comparison of baseline and week 8 contrast-enhanced CT images. Three blinded radiologists evaluated CT images and classified as optimal, incomplete or none response according to the morphologic criteria. RECIST response, early tumor shrinkage (ETS) and depth of response (DpR) were also evaluated. The Cox proportional hazards model was used to investigate the association between radiological variables and progression-free survival (PFS) and overall survival (OS).

Results

Of 395 patients who were eligible for efficacy analysis in the WJOG4407G study, 70 patients had liver-limited disease. Enhanced CT images of 57 of these patients from 22 participating centers were collected. Two patients were excluded from this analysis because their post-chemotherapy metastases were too small. Optimal morphologic response was identified in 19 of 55 patients (34.5%). The median PFS was 10.7 months for patients with optimal response and 10.1 months in those with incomplete/no response (log-rank p = 0.96). The median OS was 26.2 and 35.5 months, respectively (log-rank p = 0.062). According to univariate analysis, morphologic response was not associated with PFS or OS, whereas RECIST response was significantly associated with both PFS and OS, with ETS and DpR being associated with significantly longer PFS.

Conclusions

Morphologic response might be neither predictive nor prognostic factor in patients with CLM undergoing chemotherapy containing bevacizumab, whereas RECIST response was significantly associated with both PFS and OS.

Clinical trial identification

UMIN000022171.

Legal entity responsible for the study

West Japan Oncology Group.

Funding

West Japan Oncology Group.

Editorial Acknowledgement

Disclosure

A. Hosokawa: Honoraria: Taiho, Chugai, Takeda, Ono, Novartis, Eisai, Eli Lilly; Research funding: Taiho, Chugai, Ono, Eisai, Yakult. K. Yamazaki: Speakers’ bureau: Chugai, Takeda, Taiho, Yakult, Merck Serono, Eli Lilly, Sanofi, Bayer E. Baba: Speakers’ bureau: Chugai, Eli Lilly; Research funding: Ono, Chugai, Eli Lilly, Takeda, Taiho, Merck Serono. K. Shinozaki: Honoraria: Chugai, Takeda, Mochida, Merck Serono, Taiho, Yakult, Astellas, Novartis, Eisai, Eli Lilly, Shionogi, Kyowa Hakko Kirin, Asahi Kasei, MSD. S. Morita: Honoraria: Chugai Pharma, Daiichi Sankyo. K. Muro: Honoraria: Chugai, Taiho, Bayer, Ono, Eli Lilly, Takeda; Research funding: Ono, MSD, Daiichi Sankyo, Kyowa Hakko Kirin, Gilead Sciences, Shionogi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.